– Six Patients with TRK Fusion Cancers Enrolled; All Remain on Study –
– Three Patients with TRK Fusion Cancers Evaluable for Efficacy and All Show Objective Responses –
– Company to Host Investor Conference Call and Webcast to Review the Data on Monday, November 9, 2015 at 8:00 a.m. EST –
STAMFORD, Conn., Nov. 08, 2015 (GLOBE NEWSWIRE) — Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.